{"corpus_id":11056615,"paper_sha":"808129a820f039379de318e5d091787a627a0295","doi":"10.1056/NEJM199802123380701","arxiv_id":null,"pmid":9459643,"pmcid":null,"mag_id":2312814626,"dblp_id":null,"acl_id":null,"title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.","year":1998,"publication_date":"1998-02-12","venue":"New England Journal of Medicine","journal":{"name":"The New England journal of medicine","pages":"\n          409-15\n        ","volume":"338 7"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial"],"s2_fields_of_study":["Medicine"],"reference_count":29,"citation_count":1490,"influential_citation_count":38,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Anticoagulants","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000925"},{"d":"Combined Modality Therapy","mj":false,"ui":"D003131"},{"d":"Enoxaparin","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D017984"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Hemorrhage","mj":false,"qs":[{"q":"etiology","mj":false,"ui":"Q000209"}],"ui":"D006470"},{"d":"Heparin","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D006493"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Pulmonary Embolism","mj":false,"qs":[{"q":"etiology","mj":false,"ui":"Q000209"},{"q":"mortality","mj":false,"ui":"Q000401"},{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D011655"},{"d":"Recurrence","mj":false,"ui":"D012008"},{"d":"Survival Analysis","mj":false,"ui":"D016019"},{"d":"Thrombophlebitis","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"},{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"therapy","mj":true,"ui":"Q000628"}],"ui":"D013924"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Vena Cava Filters","mj":true,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D016306"}],"chemicals":[{"n":"Anticoagulants","ui":"D000925","reg":"0"},{"n":"Enoxaparin","ui":"D017984","reg":"0"},{"n":"Heparin","ui":"D006493","reg":"9005-49-6"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701?articleTools=true","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/808129a820f039379de318e5d091787a627a0295","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis is still a matter of debate. METHODS: Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated heparin (205 patients). The rates of recurrent venous thromboembolism, death, and major bleeding were analyzed at day 12 and at two years. RESULTS: At day 12, two patients assigned to receive filters (1.1 percent), as compared with nine patients assigned to receive no filters (4.8 percent), had had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.22; 95 percent confidence interval, 0.05 to 0.90). At two years, 37 patients assigned to the filter group (20.8 percent), as compared with 21 patients assigned to the no-filter group (11.6 percent), had had recurrent deep-vein thrombosis (odds ratio, 1.87; 95 percent confidence interval, 1.10 to 3.20). There were no significant differences in mortality or the other outcomes. At day 12, three patients assigned to low-molecular-weight heparin (1.6 percent), as compared with eight patients assigned to unfractionated heparin (4.2 percent), had had symptomatic or asymptomatic pulmonary embolism (odds ratio, 0.38; 95 percent confidence interval, 0.10 to 1.38). CONCLUSIONS: In high-risk patients with proximal deep-vein thrombosis, the initial beneficial effect of vena caval filters for the prevention of pulmonary embolism was counterbalanced by an excess of recurrent deep-vein thrombosis, without any difference in mortality. Our data also confirmed that low-molecular-weight heparin was as effective and safe as unfractionated heparin for the prevention of pulmonary embolism.","claims":[{"public_id":"cl_69b00c2279a86ff0e619462c91e9ea22","status":"active","text":"Low-molecular-weight heparin was as effective and safe as unfractionated heparin for prevention of pulmonary embolism.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_69b00c2279a86ff0e619462c91e9ea22"},{"public_id":"cl_5fcc5c2a94bc765323916daaeb8d20bd","status":"active","text":"No significant differences in mortality or other outcomes were observed between the filter and no-filter groups.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5fcc5c2a94bc765323916daaeb8d20bd"},{"public_id":"cl_e80105e9db1e735325738e6209e5fcc3","status":"active","text":"Vena caval filters increased recurrent deep-vein thrombosis at two years.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e80105e9db1e735325738e6209e5fcc3"},{"public_id":"cl_d9b1fdb37baec79597ab55ff976bf57a","status":"active","text":"Vena caval filters reduced pulmonary embolism at day 12 in high-risk patients with proximal deep-vein thrombosis.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d9b1fdb37baec79597ab55ff976bf57a"}],"concepts":[{"public_id":"co_0ab17fba31dd7f1742bd5fce1798508f","status":"active","name":"no-filter group","description":"Trial participants assigned to receive no vena caval filter.","types":["comparison group"],"aliases":["no filter"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0ab17fba31dd7f1742bd5fce1798508f"},{"public_id":"co_816ae26672bc5ac0ad819ed411fc6ec2","status":"active","name":"vena caval filters","description":"Devices placed in the vena cava to trap emboli and prevent them from reaching the lungs.","types":["medical device","intervention"],"aliases":["vena cava filter","filter"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_816ae26672bc5ac0ad819ed411fc6ec2"},{"public_id":"co_8d4575e5ffac9e7fc3eedf7e33c7065e","status":"active","name":"mortality","description":"Death rate measured as a trial outcome.","types":["outcome"],"aliases":["death"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8d4575e5ffac9e7fc3eedf7e33c7065e"},{"public_id":"co_aa00fd998ca41d9cd97ed03e851b4e0c","status":"active","name":"low-molecular-weight heparin","description":"A heparin anticoagulant formulation used as one of the randomized treatments.","types":["drug","treatment"],"aliases":["enoxaparin","LMWH"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aa00fd998ca41d9cd97ed03e851b4e0c"},{"public_id":"co_e0f94e659d243f14f77809c24b2dba19","status":"active","name":"unfractionated heparin","description":"A standard heparin anticoagulant formulation used as the comparator treatment.","types":["drug","treatment"],"aliases":["UFH"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e0f94e659d243f14f77809c24b2dba19"},{"public_id":"co_ec05a24f3660edb6c0306cafab5fc8d1","status":"active","name":"recurrent deep-vein thrombosis","description":"A new or repeated episode of deep-vein thrombosis after initial treatment.","types":["outcome","condition"],"aliases":["recurrent DVT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ec05a24f3660edb6c0306cafab5fc8d1"},{"public_id":"co_f0b64eff9b69acf1f222365eb4ed2ff5","status":"active","name":"pulmonary embolism","description":"Obstruction of the pulmonary arteries by embolic material.","types":["condition","outcome"],"aliases":["PE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f0b64eff9b69acf1f222365eb4ed2ff5"},{"public_id":"co_f9a5d198cc154cd4ef4635ea1cb9cf42","status":"active","name":"proximal deep-vein thrombosis","description":"Thrombosis in the proximal deep veins, used here as the enrolled high-risk condition.","types":["condition"],"aliases":["proximal DVT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f9a5d198cc154cd4ef4635ea1cb9cf42"}],"external_ids":{"DOI":"10.1056/NEJM199802123380701","ArXiv":null,"PubMed":9459643,"PubMedCentral":null,"MAG":2312814626,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701?articleTools=true","landing_url":"https://www.semanticscholar.org/paper/808129a820f039379de318e5d091787a627a0295","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632262,"paper_uid":"7309b1bf-e756-4256-83fc-d73a4ae68dfa","canonical_identity":{"paper_id":632262,"paper_uid":"7309b1bf-e756-4256-83fc-d73a4ae68dfa","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/11056615"}